Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucagon-like insulinotropic peptides, compositions and methods

a technology of insulinotropic peptides and glucagon, which is applied in the field of pharmaceutical and organic chemistry, can solve the problems of excessive liver glucose production, elevated blood sugar levels, and investigators' questions about whether glp-1 is in fact a hormone, and achieve the effect of enhancing the expression of insulin

Inactive Publication Date: 2007-06-19
ELI LILLY & CO
View PDF20 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new compound that can be used to treat diabetes. This compound contains a combination of a divalent metal cation and a specific formula. The compound has a certain isoelectric point and can precipitate with certain amino acids. The invention also includes a pharmaceutical composition containing this compound and a method for enhancing insulin expression and treating diabetes.

Problems solved by technology

The principal recognized actions of pancreatic glucagon, however, are to promote hepatic glycogenolysis and glyconeogenesis, resulting in an elevation of blood sugar levels.
The failure to identify any physiological role for GLP-1 caused some investigators to question whether GLP-1 was in fact a hormone and whether the relatedness between glucagon and GLP-1 might be artifactual.
The latter defect results in excessive production of glucose from the liver.
However, the long-term stability of GLP-1, particularly GLP-1 as a component of a pharmaceutical composition for administration to mammals, is questionable.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0099]Individual aliquots of 5 different GLP-1 molecules were prepared by well-known, solid phase peptide synthesis and were lyophilized in small vials. Portions of 0.1M HEPES (N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]) buffers at pH 7.4 containing various levels of zinc chloride. were added to the aliquots to obtain a protein concentration of about 0.1 mg / mL. The samples were mixed and stored, at ambient temperature (22° C.) for about 18 hours. The mixtures were then centrifuged (Fisher Model 235C micro-centrifuge) for 5 minutes. The clear supernatants were pipetted from the tubes. The protein content of the supernatants was estimated by measuring their absorbance at 280 nm in a spectrophotometer (Gilford 260). The theoretical absorbance value for a 0.1 mg / mL solution of the GLP-1 molecules at this wavelength in the 1 cm cuvettes is 0.207. The results of this experiment are shown in Table 1.

[0100]

TABLE 1280 nm Absorbanceα-methly-Gly8-Zn / GLP-1Gly8-Val8-Ala8-Gln21Molecu...

example 2

[0102]5 mg of GLP-1 (7-36)NH2 was completely dissolved in 2.5 mL of pH 7.4., zinc-free 0.1M HEPES buffer. An additional 2.5 mL of pH 7.4, 0.1M HEPES buffer containing 0.6 mM zinc chloride was quickly added. The approximate molar ratio of zinc to GLP-1 (7-36)NH2 in this sample is 1 to 1. The solution immediately became cloudy and precipitation soon formed. The mixture was stored at ambient temperature (22° C.) for 18 hours.

[0103]The precipitate became firmly attached to the bottom of the glass vial. The supernatant was completely decanted by pipette. The precipitate was then completely dissolved in 5.0 mL of 0.01N hydrochloric acid. The absorbance at 280 nm was determined for both the supernatant and redissolved precipitate solutions. The zinc levels in these solutions were quantitated by atomic absorption spectrophotometry. The results of this experiment are shown in Table 2.

[0104]

TABLE 2Zinc Concentration280 nm Absorbancein Parts per MillionSupernatant (5 ml)0.1189.02Redissolved Pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
total volumeaaaaaaaaaa
Login to View More

Abstract

The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

Description

[0001]This application is a continuation of U.S. Ser. No. 10 / 125,255, filed Apr. 17, 2002, now U.S. Pat. No. 6,703,365 , which is a continuation of U.S. Ser. No. 08 / 407,831, now U.S. Pat. No. 5,705,483, filed Mar. 21, 1995, which is a continuation-in-part of U.S. Ser. No. 08 / 164,277, filed Dec. 9, 1993, now abandoned.BACKGROUND OF THE INVENTION [0002]This invention relates to the field of pharmaceutical and organic chemistry and provides novel compounds, and pharmaceutical compositions thereof, which are useful for enhancing the expression of insulin from mammalian pancreatic B-type islet cells and for treating maturity onset diabetes mellitus in a mammal.[0003]The endocrine secretions of the pancreatic islets are under complex control not only by blood-borne metabolites (glucose, amino acids, catecholamines, etc.), but also by local paracrine influences. The major pancreatic islet hormones (glucagon, insulin and somatostatin) interact amongst their specific cell types (A, B, and D ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/26A61K38/00A61K38/28A61K47/02A61K47/42A61P3/08A61P3/10A61P43/00C07KC07K14/575C07K14/605C07K14/62
CPCA61K47/48238C07K14/605A61K38/00Y10S514/866Y10S977/904Y10S977/915Y10S977/773A61K47/62A61P3/00A61P3/10A61P3/08A61P43/00C07K17/14
Inventor GALLOWAY, JOHN A.HOFFMANN, JAMES A.
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com